ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 10.99
-0.11 (-0.99%)
At close: Feb 13, 2026
ChemPartner PharmaTech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,063 | 965.1 | 1,132 | 1,321 | 1,685 | 1,476 |
Other Revenue | 5.1 | 5.1 | 6.5 | 5.54 | 6.16 | 6 |
| 1,069 | 970.2 | 1,138 | 1,327 | 1,691 | 1,482 | |
Revenue Growth (YoY) | 5.72% | -14.77% | -14.19% | -21.54% | 14.11% | 11.58% |
Cost of Revenue | 779.52 | 768.13 | 859.37 | 999.55 | 1,158 | 918.57 |
Gross Profit | 289 | 202.07 | 279 | 327.04 | 532.22 | 563.02 |
Selling, General & Admin | 241.1 | 203.62 | 256.78 | 306.24 | 331.24 | 279.27 |
Research & Development | 56.13 | 59.55 | 77.47 | 92.28 | 124.65 | 71.68 |
Other Operating Expenses | 10.7 | 4.92 | 5.66 | 7.48 | 5.69 | 5.14 |
Operating Expenses | 341.18 | 299.33 | 344.57 | 422.6 | 466.91 | 361.41 |
Operating Income | -52.18 | -97.26 | -65.57 | -95.56 | 65.31 | 201.61 |
Interest Expense | -35.76 | -26.1 | -31.3 | -66.48 | -78.73 | -52.17 |
Interest & Investment Income | 29.17 | 22.25 | 14.79 | 1,403 | 14.72 | 97.82 |
Currency Exchange Gain (Loss) | 10.88 | 10.88 | 3.52 | 44.05 | -6.12 | -8.59 |
Other Non Operating Income (Expenses) | 11.62 | -1.05 | -2.41 | -3.5 | 1.11 | -3.17 |
EBT Excluding Unusual Items | -36.26 | -91.28 | -80.97 | 1,281 | -3.71 | 235.51 |
Impairment of Goodwill | -139.26 | -139.26 | -816.73 | -232.4 | -367.6 | -42 |
Gain (Loss) on Sale of Investments | -2.31 | -2.3 | -0.92 | -0.04 | 0.06 | - |
Gain (Loss) on Sale of Assets | 10.6 | 8.43 | -0 | -0.15 | -0.02 | -0.03 |
Asset Writedown | -7.55 | -21.49 | -50.45 | -312.89 | -5.67 | -0.58 |
Other Unusual Items | 24.93 | 14.25 | 9.3 | 8.85 | 15.91 | 0.6 |
Pretax Income | -149.86 | -231.64 | -939.77 | 744.72 | -361.03 | 193.5 |
Income Tax Expense | 7.71 | -5.13 | -22.83 | 366.34 | 41.07 | 39.47 |
Earnings From Continuing Operations | -157.57 | -226.51 | -916.94 | 378.38 | -402.1 | 154.03 |
Minority Interest in Earnings | -0.15 | 0.04 | 0.19 | 0.21 | -0.15 | 0.52 |
Net Income | -157.72 | -226.47 | -916.75 | 378.59 | -402.25 | 154.55 |
Net Income to Common | -157.72 | -226.47 | -916.75 | 378.59 | -402.25 | 154.55 |
Net Income Growth | - | - | - | - | - | 11.25% |
Shares Outstanding (Basic) | 504 | 503 | 498 | 498 | 497 | 500 |
Shares Outstanding (Diluted) | 504 | 503 | 498 | 498 | 497 | 500 |
Shares Change (YoY) | 4.98% | 1.01% | 0.02% | 0.31% | -0.64% | - |
EPS (Basic) | -0.31 | -0.45 | -1.84 | 0.76 | -0.81 | 0.31 |
EPS (Diluted) | -0.31 | -0.45 | -1.84 | 0.76 | -0.81 | 0.31 |
EPS Growth | - | - | - | - | - | 11.25% |
Free Cash Flow | 123.51 | 98.96 | -50.3 | -73.74 | 92.22 | -50.87 |
Free Cash Flow Per Share | 0.24 | 0.20 | -0.10 | -0.15 | 0.19 | -0.10 |
Dividend Per Share | - | - | - | - | - | 0.070 |
Gross Margin | 27.05% | 20.83% | 24.51% | 24.65% | 31.48% | 38.00% |
Operating Margin | -4.88% | -10.03% | -5.76% | -7.20% | 3.86% | 13.61% |
Profit Margin | -14.76% | -23.34% | -80.53% | 28.54% | -23.79% | 10.43% |
Free Cash Flow Margin | 11.56% | 10.20% | -4.42% | -5.56% | 5.46% | -3.43% |
EBITDA | 1.77 | -39.39 | -2.48 | 14.67 | 176.97 | 305.22 |
EBITDA Margin | 0.17% | -4.06% | -0.22% | 1.10% | 10.47% | 20.60% |
D&A For EBITDA | 53.95 | 57.87 | 63.1 | 110.23 | 111.66 | 103.61 |
EBIT | -52.18 | -97.26 | -65.57 | -95.56 | 65.31 | 201.61 |
EBIT Margin | -4.88% | -10.02% | -5.76% | -7.20% | 3.86% | 13.61% |
Effective Tax Rate | - | - | - | 49.19% | - | 20.40% |
Revenue as Reported | 1,069 | 970.2 | 1,138 | 1,327 | 1,691 | 1,482 |
Advertising Expenses | - | 0.47 | 0.73 | 0.68 | 0.76 | 6.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.